Literature DB >> 17591840

Cetuximab: clinical results in colorectal cancer.

E Maiello1, F Giuliani, V Gebbia, A Piano, R Agueli, G Colucci.   

Abstract

In recent years, the introduction of targeted therapies into clinical practice seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC), mainly when they are employed in combination with optimal chemotherapy and/or radiotherapy. In this paper, we focus on Cetuximab and its role in the treatment of mCRC.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17591840     DOI： 10.1093/annonc/mdm216

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  5 in total

1.  LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation.

Authors:  Zhihua Pan; Chaoqun Liu; Yunfei Zhi; Zhiyue Xie; Ling Wu; Muhong Jiang; Yujie Zhang; Rui Zhou; Liang Zhao
Journal:  Oncogene       Date:  2021-03-08       Impact factor: 9.867

2.  A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).

Authors:  José María Viéitez; Manuel Valladares; Ignacio Peláez; Luis de Sande González; Jesús García-Foncillas; José Luis García-López; Carlos García-Girón; Margarita Reboredo; Humberto Bovio; Angel Jiménez Lacave
Journal:  Invest New Drugs       Date:  2010-03-06       Impact factor: 3.850

Review 3.  Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

Authors:  Jesús García-Foncillas; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2010-08       Impact factor: 3.340

Review 4.  Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.

Authors:  Xuezhen Zeng; Simon E Ward; Jingying Zhou; Alfred S L Cheng
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

5.  A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer.

Authors:  Justin M Balko; Esther P Black
Journal:  BMC Cancer       Date:  2009-05-13       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.